Previously based in Maine, Biousian Biosystems Inc (BBI) is focused to improving the lives of patients living in chronic pain or struggling conditions which lead to chronic pain. Using its Carbosyn technology platform, BBI builds drugs that have unique selectivity and potency for targets called G-protein coupled receptor or âGPCRsâ. The company has specific strengths in related medicinal chemistries and pharmacology. For clinical validation BBI strives to work closely with development partners whose interests and expertise include seeking FDA approval and subsequent product commercializatio
